Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 5/2011

01.10.2011

Novel Concepts in the Genesis of Hypertension: Role of LOX-1

verfasst von: Ping Luo, Meiling Yan, Edward D. Frohlich, Jawahar L. Mehta, Changping Hu

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Hypertension is a common disease and a potent risk factor for cardiovascular disease. Tremendous strides have been made in understanding its genesis in the last 2 decades. Hypertension is often clustered with other cardiovascular risk factors, such as dyslipidemia and diabetes. The state of hypertension is often associated with increased vascular oxidative stress. Oxidative stress promotes proliferation and hypertrophy of vascular smooth muscle cell and collagen deposition, leading to thickening of the vascular media and narrowing of the vascular lumen. Oxidative stress also injures endothelium, impairs endothelium-dependent vascular relaxation and increases vascular contractile activity. Further, oxidative stress also oxidizes LDL-cholesterol. It has been shown that oxidized low-density lipoprotein (ox-LDL) activates renin-angiotensin system (RAS) and angiotensin II via its type 1 receptor activates ox-LDL receptor LOX-1. This mutually facilitative cross-talk between ox-LDL and RAS may be an important component in the development of hypertension. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a receptor for ox-LDL. This review summarizes the role of LOX-1 in the pathogenesis of hypertension.
Literatur
1.
Grossman E. Does increased oxidative stress cause hypertension? Diabetes Care. 2008;31:S185–9.PubMedCrossRef
2.
Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93:621–35 (Frohlich ED, Editor).PubMedCrossRef
3.
Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73–7.PubMedCrossRef
4.
Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J. 1998;334:9–13.PubMed
5.
Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K, et al. Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:955–60.PubMedCrossRef
6.
Chen M, Kakutani M, Naruko T, Ueda M, Narumiya S, Masaki T, et al. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun. 2001;282:153–8.PubMedCrossRef
7.
Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem. 2008;283:10226–31.PubMedCrossRef
8.
Hu CP, Dandapat A, Liu Y, Hermonat PL, Mehta JL. Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF-beta1 delivered by AAV in mouse cardiomyocytes. Am J Physiol Heart Circ Physiol. 2007;293:H1833–8.PubMedCrossRef
9.
Hu CP, Mehta JL. Biology of LOX-1 in relation to atherogenesis. Future lipidol. 2008;3:689–96.CrossRef
10.
Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized low-density lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun. 1997;237:496–8.PubMedCrossRef
11.
Hu C, Chen J, Dandapat A, Fujita Y, Inoue N, Kawase Y, et al. LOX-1 abrogation reduces myocardial ischemia-reperfusion injury in mice. J Mol Cell Cardiol. 2008;44:76–83.PubMedCrossRef
12.
Sankaralingam S, Xu H, Jiang Y, Sawamura T, Davidge ST. Evidence for increased methylglyoxal in the vasculature of women with preeclampsia: role in upregulation of LOX-1 and arginase. Hypertension. 2009;54:897–904.PubMedCrossRef
13.
Navarra T, Del Turco S, Berti S, Basta G. The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb. 2010;17:317–31.PubMedCrossRef
14.
Aoyama T, Fujiwara H, Masaki T, Sawamura T. Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultured endothelial cells. J Mol Cell Cardiol. 1999;31:2101–14.PubMedCrossRef
15.
Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL. Molecular dissection of angiotensin II-activated human LOX-1 promoter. Arterioscler Thromb Vasc Biol. 2006;26:1163–8.PubMedCrossRef
16.
Hofnagel O, Luechtenborg B, Stolle K, Lorkowski S, Eschert H, Plenz G, et al. Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:1789–95.PubMedCrossRef
17.
Murase T, Kume N, Korenaga R, Ando J, Sawamura T, Masaki T, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:328–33.PubMed
18.
Gobal F, Deshmukh A, Shah S, Mehta JL. Triad of metabolic syndrome, chronic kidney disease, and coronary heart disease with a focus on microalbuminuria death by overeating. J Am Coll Cardiol. 2011;57:2303–8.PubMedCrossRef
19.
Ward NC, Croft KD. Hypertension and oxidative stress. Clin Exp Pharmacol Physiol. 2006;33:872–6.PubMedCrossRef
20.
Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296:R195–200.PubMedCrossRef
21.
Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002;346:1954–62.PubMedCrossRef
22.
Lip GY, Edmunds E, Nuttall SL, Landray MJ, Blann AD, Beevers DG. Oxidative stress in malignant and non-malignant phase hypertension. J Hum Hypertens. 2002;16:333–6.PubMedCrossRef
23.
Lee VM, Quinn PA, Jennings SC, Ng LL. Neutrophil activation and production of reactive oxygen species in pre-eclampsia. J Hypertens. 2003;21:395–402.PubMedCrossRef
24.
Kimura H, Kon N, Furukawa S, Mukaida M, Yamakura F, Matsumoto K, et al. Effect of endurance exercise training on oxidative stress in spontaneously hypertensive rats (SHR) after emergence of hypertension. Clin Exp Hypertens. 2010;32:407–15.PubMedCrossRef
25.
Hu C, Dandapat A, Sun L, Marwali MR, Inoue N, Sugawara F, et al. Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension. 2008;52:556–62.PubMedCrossRef
26.
Naito Y, Hirotani S, Sawada H, Akahori H, Tsujino T, Masuyama T. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension. 2011;57:497–504.PubMedCrossRef
27.
Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;295:H454–65.PubMedCrossRef
28.
Bełtowski J, Borkowska E, Wójcicka G, Marciniak A. Regulation of renal ouabain-resistant Na+-ATPase by leptin, nitric oxide, reactive oxygen species, and cyclic nucleotides: implications for obesity-associated hypertension. Clin Exp Hypertens. 2007;29:189–207.PubMedCrossRef
29.
Dunbar DR, Khaled H, Evans LC, Al-Dujaili EA, Mullins LJ, Mullins JJ, et al. Transcriptional and physiological responses to chronic ACTH treatment by the mouse kidney. Physiol Genomics. 2010;40:158–66.PubMedCrossRef
30.
Yogi A, Callera GE, O’Connor SE, He Y, Correa JW, Tostes RC, et al. Dysregulation of renal transient receptor potential melastatin 6/7 but not paracellin-1 in aldosterone-induced hypertension and kidney damage in a model of hereditary hypomagnesemia. J Hypertens. 2011;29:1400–10.PubMedCrossRef
31.
Ilhan S, Oktar S, Sahna E, Aksulu HE. Salt and nitric oxide inhibition induced hypertension: the role of prostacycline and 8-isoprostane. Clin Exp Hypertens. 2011;33:84–8.PubMedCrossRef
32.
Reis F, Rocha-Pereira P, Teixeira de Lemos E, Parada B, Baptista S, Figueiredo A, et al. Oxidative stress in cyclosporine-induced hypertension: evidence of beneficial effects or tolerance development with nitrate therapy. Transplant Proc. 2007;39:2494–500.PubMedCrossRef
33.
Nakano A, Inoue N, Sato Y, Nishimichi N, Takikawa K, Fujita Y, et al. LOX-1 mediates vascular lipid retention under hypertensive state. J Hypertens. 2010;28:1273–80.PubMed
34.
Saeed A, Dibona GF, Marcussen N, Guron G. High-NaCl intake impairs dynamic autoregulation of renal blood flow in ANG II-infused rats. Am J Physiol Regul Integr Comp Physiol. 2010;299:R1142–9.PubMedCrossRef
35.
Liu R, Ren Y, Garvin JL, Carretero OA. Superoxide enhances tubuloglomerular feedback by constricting the afferent arteriole. Kidney Int. 2004;66:268–74.PubMedCrossRef
36.
Wang T, Takabatake T. Effects of vasopeptidase inhibition on renal function and tubuloglomerular feedback in spontaneously hypertensive rats. Hypertens Res. 2005;28:611–8.PubMedCrossRef
37.
Hirooka Y. Oxidative stress in the cardiovascular center has a pivotal role in the sympathetic activation in hypertension. Hypertens Res. 2011;34:407–12.PubMedCrossRef
38.
Cheng WH, Lu PJ, Ho WY, Tung CS, Cheng PW, Hsiao M, et al. Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure. Circ Res. 2010;106:788–95.PubMedCrossRef
39.
Ferrario C. Angiotensin-converting enzyme 2 and angiotensin (1–7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515–21.PubMedCrossRef
40.
Brody MJ. Central nervous system and mechanisms of hypertension. Clin Physiol Biochem. 1988;6:230–9.PubMed
41.
Peterson JR, Sharma RV, Davisson RL. Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep. 2006;8:232–41.PubMedCrossRef
42.
Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, et al. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res. 2002;91:1038–45.PubMedCrossRef
43.
Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 2004;95:210–6.PubMedCrossRef
44.
Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol. 2003;23:776–82.PubMedCrossRef
45.
Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2:582–93.PubMedCrossRef
46.
Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension. 2008;52:256–63.PubMedCrossRef
47.
Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–60.PubMedCrossRef
48.
Nguyen Dinh Cat A, Touyz RM. Cell signaling of angiotensin II on vascular tone: novel mechanisms. Curr Hypertens Rep. 2011;13:122–8.PubMedCrossRef
49.
Re RN. The cellular biology of angiotensin; paracrine, autocrine and intracrine actions in cardiovascular tissues. J Mol Cell Cardiol. 1989;2:63–9.CrossRef
50.
Re RN. The nature of intracrine peptide mormone actions. Hypertension. 1999;34:534–8.PubMed
51.
Re RN, Cook JL. Chapter 9 Intracrine function from angiotensin to stem cells. In: Frohlich ED, Re RN, editors. The local cardiac renin-angiotensin aldosterone system. New York: Springer-Science Business Media, LLC; 2009. p. 91–100.CrossRef
52.
Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292–316.PubMedCrossRef
53.
Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res. 2003;26:937–43.PubMedCrossRef
54.
Catar RA, Muller G, Heidler J, Schmitz G, Bornstein SR, Morawietz H. Low-density lipoproteins induce the renin-angiotensin system and their receptors in human endothelial cells. Horm Metab Res. 2007;39:801–5.PubMedCrossRef
55.
Chen J, Mehta JL. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. Curr Hypertens Rep. 2006;8:139–43.PubMedCrossRef
56.
Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis. 2006;184:295–301.PubMedCrossRef
57.
Marsche G, Levak-Frank S, Quehenberger O, Heller R, Sattler W, Malle E. Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J. 2001;15:1095–7.PubMed
58.
Oka K, Sawamura T, Kikuta K, Itokawa S, Kume N, Kita T, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci USA. 1998;95:9535–40.PubMedCrossRef
59.
Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM, et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci USA. 2003;100:1274–9.PubMedCrossRef
60.
Shimaoka T, Kume N, Minami M, Hayashida K, Sawamura T, Kita T, et al. LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria. J Immunol. 2001;166:5108–14.PubMed
61.
Cominacini L, Fratta Pasini A, Garbin U, Pastorino A, Rigoni A, Nava C, et al. The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells. J Am Coll Cardiol. 2003;41:499–507.PubMedCrossRef
62.
Murphy JE, Tacon D, Tedbury PR, Hadden JM, Knowling S, Sawamura T, et al. LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. Biochem J. 2006;393:107–15.PubMedCrossRef
63.
Chen X, Zhang T, Du G. Advanced glycation end products serve as ligands for lectin-like oxidized low-density lipoprotein receptor-1(LOX-1): biochemical and binding characterizations assay. Cell Biochem Funct. 2008;26:760–70.PubMedCrossRef
64.
Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation. 2000;102:1970–6.PubMed
65.
Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem. 2009;55:285–94.PubMedCrossRef
66.
Taye A, Saad AH, Kumar AH, Morawietz H. Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. Eur J Pharmacol. 2010;627:42–8.PubMedCrossRef
67.
Nagase M, Kaname S, Nagase T, Wang G, Ando K, Sawamura T, et al. Expression of LOX-1, an oxidized low-density lipoprotein receptor, in experimental hypertensive glomerulosclerosis. J Am Soc Nephrol. 2000;11:1826–36.PubMed
68.
Chiba Y, Ando K, Fujita T. The protective effects of taurine against renal damage by salt loading in Dahl salt-sensitive rats. J Hypertens. 2002;20:2269–74.PubMedCrossRef
69.
Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation. 1999;100:899–902.PubMed
70.
Kang BY, Hu C, Ryu S, Khan JA, Biancolella M, Prayaga S, et al. Genomics of cardiac remodeling in angiotensin II-treated wild-type and LOX-1-deficient mice. Physiol Genomics. 2010;42:42–54.PubMedCrossRef
71.
Kang BY, Khan JA, Ryu S, Shekhar R, Seung KB, Mehta JL. Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J Cardiovasc Pharmacol. 2010;55:417–24.PubMedCrossRef
72.
Kang BY, Mehta JL. Rosuvastatin attenuates Ang II–mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharmacol Ther. 2009;14:283–91.PubMedCrossRef
73.
Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension. 2005;45:538–44.PubMedCrossRef
74.
Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295:F53–9.PubMedCrossRef
75.
Hu C, Kang BY, Megyesi J, Kaushal GP, Safirstein RL, Mehta JL. Deletion of LOX-1 attenuates renal injury following angiotensin II infusion. Kidney Int. 2009;76:521–7.PubMedCrossRef
76.
Kang BY, Hu C, Prayaga S, Khaidakov M, Sawamura T, Seung KB, et al. LOX-1 dependent overexpression of immunoglobulins in cardiomyocytes in response to angiotensin II. Biochem Biophys Res Commun. 2009;379:395–9.PubMedCrossRef
77.
Kishimoto C, Takamatsu N, Kawamata H, Shinohara H, Ochiai H. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol. 2000;36:1979–84.PubMedCrossRef
Metadaten
Titel
Novel Concepts in the Genesis of Hypertension: Role of LOX-1
verfasst von
Ping Luo
Meiling Yan
Edward D. Frohlich
Jawahar L. Mehta
Changping Hu
Publikationsdatum
01.10.2011
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5/2011
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-011-6337-1

Weitere Artikel der Ausgabe 5/2011

Cardiovascular Drugs and Therapy 5/2011 Zur Ausgabe

OriginalPaper

LOX-1 and Angiotensin Receptors, and Their Interplay

OriginalPaper

LOX-1/LOXIN: The Yin/Yang of Atheroscleorosis

OriginalPaper

Do Atherosclerosis and Obesity-Associated Susceptibility to Cancer Share Causative Link to oxLDL and LOX-1?

OriginalPaper

Oxidized Low Density Lipoproteins-Do We Know Enough About Them?

OriginalPaper

LOX-1, Oxidative Stress and Inflammation: A Novel Mechanism for Diabetic Cardiovascular Complications

Review Article

LOX-1 Transcription

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise